Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC 2 . VIP is a 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC 1 / VPAC 2 to design nine simplified VIP analogs that could have high affinity and selectivity for each VPAC or that retained high affinity for both VPACs and were metabolically stable. From binding studies of their abilities to directly interact with hVPAC 1
I-[Ala
]VIP was much more metabolically stable than 125 I-VIP. The availability of these simplified analogs of VIP, which are metabolically stable and have either hVPAC 1 selectivity or retain high affinity for both hVPACs, should be useful for exploring the role of VPAC subtypes in mediating VIPs' actions as well as being useful therapeutically and for exploring the usefulness of VIP receptor imaging of tumors and VIP receptor-mediated tumor cytotoxicity.
Vasoactive intestinal peptide (VIP) is a widely distributed neurotransmitter that is thought to play an important role in a number of physiological and pathological processes (Dockray, 1994; Gozes and Brenneman, 2000) . VIP is proposed to play a role in a number of disease states (Gozes and Furman, 2004) , including a role in growth of cancer cells (Moody, 1996; Moody et al., 2003; Gozes and Furman, 2004) , various central nervous system disorders (Gozes and Brenneman, 2000; Dogrukol-Ak et al., 2004; Gozes and Furman, 2004) , various inflammatory disorders such as rheumatoid arthritis (Gozes and Brenneman, 2000) , and various immunological disorders (Delgado et al., 2004) , and a role has been proposed for VIP in treatment of asthma (Groneberg et al., 2001) , impotence (Sandhu et al., 1999; Kalsi et al., 2002) , and for treatment of septic shock (Kalsi et al., 2002; Delgado et al., 2004) , central nervous system disorders (Gozes and Brenneman, 2000; Dogrukol-Ak et al., 2004) , and diabetes (Yung et al., 2003) .
In almost all cases, which VIP receptor subtype is mediating the action of VIP in these various conditions, is unclear. The actions of VIP are mediated by two receptor subtypes (VPAC 1 and VPAC 2 ), which have different pharmacology and distributions (Dockray, 1994; Harmar et al., 1998) . VIP has high affinity for both VIP receptor subtypes and therefore does not discriminate between the two VIP receptor subtypes (Harmar et al., 1998) . Furthermore, VIP is a 28-amino acid peptide that undergoes rapid degradation in vivo with a half-life less than 1 min (Domschke et al., 1978) . Therefore, simplified VIP analogs that retain high affinity and have selectivity for one VIP receptor subtype, especially if metabolically stable, could be of value in investigating VIP's roles in physiological or pathological states as well as its use as a possible therapeutic agent. Furthermore, a metabolically stable, simplified VIP analog that retained high affinity for both VIP receptor subtypes could be useful for imaging tumors overexpressing VIP receptors as well as possibly for VIP receptor-directed antitumor treatment.
Recently, we (Igarashi et al., 2002a,b) and others (Nicole et al., 2000) have performed alanine scanning as well as Damino acid scanning of VIP (Igarashi et al., 2002a,b) to define the VIP pharmacophore for the human VPAC 1 and human VPAC 2 receptors. These studies (Nicole et al., 2000; Igarashi et al., 2002a,b) provided information that could be helpful in the design of a simplified VIP analog that had either selective high affinity for one VPAC or that retained high affinity for both and yet might be metabolically stable. The latter point is supported by results of a previous study that demonstrated a polyalaninated VIP analog with high affinity for VPAC 1 was much more metabolically stable than VIP (Igarashi et al., 2002b) . However, in that study (Igarashi et al., 2002b) , the selectivity of this VIP analog for VPAC 1 (analog 2 in the present study) was not determined. Therefore, in the present study we used an analysis of these study results (Nicole et al., 2000; Igarashi et al., 2002a,b) on the VIP pharmacophore to design five additional VIP analogs with multiple alanine replacements that should have high affinity retained for VPAC 1 and three analogs that should have high affinity retained for VPAC 2 and assessed their affinities for each VPAC, their selectivity, and metabolic stability of selected analogs.
Materials and Methods
Materials. PANC1 human pancreatic cancer cells and Sup T 1 human lymphoblastoma cells were obtained from American Type Culture Collection (Manassas, VA). Porcine VIP was from Bachem Biosciences (King of Prussia, PA); basal medium Eagle amino acid mixture, basal medium Eagle vitamin solution, fetal bovine serum, and Lipofectamine transfection reagent were from Invitrogen (Carlsbad, CA); Geneticin (G418 sulfate) was from Mediatech (Herndon, VA); bacitracin, soybean trypsin inhibitor, 3-isobutyl-1-methylxanthine (IBMX), and alumina were from Sigma-Aldrich (St. Louis, MO); AG50W-X4 resin was from Bio-Rad (Hercules, CA); bovine serum albumin (BSA) fraction V was from MP Biomedicals (Irvine, CA); 125 I-VIP (2200 Ci/mmol) and 125 I-PACAP(1-27) (2200 Ci/mmol) were from PerkinElmer Life and Analytical Sciences (Boston, MA); Na 125 I (2200 Ci/mmol) and [2-3 H]adenine (22 Ci/mmol) were from GE Healthcare (Piscataway, NJ); 1,3,4,6-tetrachloro 3␣-,6␣-diphenylglycouril was from Pierce Chemical (Rockford, IL); HEPES was from Roche Diagnostics (Indianapolis, IN). Dulbecco's modified Eagle's medium (DMEM), RPMI 1640 medium, and Ham's F-12K medium were from Biofluids (Rockville, MD). The standard incubation solution contained 24.5 mM HEPES, pH 7.45, 98 mM NaCl, 6 mM KCl, 2 mM KH 2 PO 4 , 5 mM sodium pyruvate, 5 mM sodium fumarate, 5 mM sodium glutamate, 2 mM glutamine, 11.5 mM glucose, 0.5 mM CaCl 2 , 1 mM MgCl 2 , 1% (w/v) BSA, 0.2% (w/v) soybean trypsin inhibitor, 1% (v/v) amino acid mixture, and 1% (v/v) essential vitamin mixture.
Preparation of Peptides. Multiple alanine-substituted VIP analogs (VPAC-A-1 to 9; Table 1 and Fig. 1 ) were synthesized using standard solid phase methods as described previously (Sasaki and Coy, 1987; Igarashi et al., 2002a) . Homogeneity of the peptides was assessed by thin layer chromatography and analytical reverse-phase PHLC with the purity Ն97% for each peptide.
Construction of PANC1 Cells Stably Transfected with hVPAC 2 -R and hVPAC 2 -R. Construction of the human VPAC 1 receptor (hVPAC 1 -R) and human VPAC 2 (hVPAC 2 -R) receptor expression vector and construction of hVPAC 1 -R or hVPAC 2 -R stably transfected PANC1 cells (hVPAC 1 -R or hVPAC 2 -R/PANC1 cells) were described previously (Ito et al., 2001; Igarashi et al., 2002a) .
Cell Culture. The hVPAC 1 -R/PANC1 cells and hVPAC 2 -R/ PANC1 cells were grown in DMEM supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) antibiotics, and 300 g/ml G418. Sup T 1 human lymphoblastoma cells were grown in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum, and 1% (v/v) antibiotics, adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate as recommended by American Type Culture Collection and were maintained in incubators at 37°C in an atmosphere of 5% CO 2 and 95% air. T47D human breast cancer cells were grown in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum 1% (v/v) penicillin/streptomycin, and 0.2 IU/ml insulin and were maintained in incubators at 37°C in an atmosphere of 5% CO 2 and 95% air. (O'Donnell et al., 1994a,b; Gourlet et al., 1997b ) at a specific activity of 2200 Ci/mmol was prepared by a modification of the methods described previously (Zhou et al., 1989) . In brief, 0.8 g of 1,3,4,6-tetrachloro 3␣-,6␣-diphenylglycouril in chloroform was transferred to a vial, dried under a stream of nitrogen, and washed with 100 l of 0.5 M KH 2 PO 4 , pH 8.0. To this vial, 20 l of 0.5 M KH 2 PO 4 , pH 8.0, 8 g of peptide in 4 l of water, and 2 mCi (20 l) of Na 125 I were added, mixed gently, and incubated at room temperature for 6 min. The incubation was stopped by the addition of 100 l of distilled water. The iodination mixture was applied to a Sep-Pak C18 (Waters, Milford, MA), and free 125 I was eluted with 5 ml of water followed by 5 ml of 0.1% (v/v) trifluoroacetic acid. The radiolabeled peptides were eluted with 200 l of sequential elutions (ϫ10) with 60% acetonitrile in 0.1% trifluoroacetic acid. The two or three fractions with the highest radioactivity were combined and purified on a reverse-phase, high-performance liquid chromatography with a Vydac C18 column (0.46 ϫ 25 cm). The column was eluted with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (v/v) from 16 to 60% acetonitrile in 60 min, and 1-ml fractions were collected and assayed for radioactivity and receptor binding. The pH of the pooled fractions was adjusted to 7 using 0.2 M Tris, pH 9.5, and radioligands were stored in aliquots with 0.5% bovine serum albumin (w/v) at Ϫ20°C.
125
I- [Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 ]VIP (VIP analog 2; Table 1 ; Igarashi et al., 2002a) and 8, 9, 16, 19, 24, 25 ]VIP (VIP analog 8; Table 1 ) were prepared using the same procedures.
Binding Studies. Binding of 125 I-VIP to hVPAC 1 -R/PANC1 and T47D cells, and binding of 125 I-PACAP(1-27) to hVPAC 2 -R/PANC1 were performed by incubation in standard incubation solution containing 0.05% (w/v) bacitracin for 60 min at room temperature and as described previously (Ito et al., 2000; Igarashi et al., 2002a,b) . To assess VPAC 2 -R affinities in Sup T 1 human lymphoblastoma cells, binding study was performed using 125 I-Ro 25-1553 in standard incubation solution containing 0.05% (w/v) bacitracin for 60 min at 37°C, because 125 I-VIP and 125 I-PACAP(1-27) were rapidly degraded in these cells even with protease inhibitors present. The separation of bound from free radioactivity was obtained by centrifugation of cells through 2% (w/v) BSA in standard incubation solution. The tubes were washed twice with 2% (w/v) BSA in standard incubation solution and radioactivity was counted. Nonsaturable binding for 125 I-VIP, 125 I-PACAP(1-27), or 125 I-Ro 25-1553 was less than 5% of total binding.
For all peptides, the IC 50 was calculated, which was the concentration that gave half-maximal inhibition of that seen with a saturating concentration of VIP (1 M). The IC 50 was calculated using the curve-fitting program Kaleidagraph.
cAMP Assay. T47D cells (0.05 ϫ 10 6 cells), hVPAC 1 -R/PANC1 (0.05 ϫ 10 6 cells), and hVPAC 2 -R/PANC1 (0.05 ϫ 10 6 cells) were plated on 24-well plates and incubated for 48 h at 37°C with media containing 10% FBS (v/v). The media were then replaced with media supplemented with 2% FBS (v/v) and 2 Ci/ml [2-3 H]adenine. Cells were incubated for an additional 48 h at 37°C. The media were removed, and cells were incubated in the 500 l of DMEM containing 1% (w/v) BSA and 0.5 mM IBMX with or without peptides at various concentrations for 1 h at 37°C. Reactions were terminated by the addition of 120 l of cAMP stopping solution [2% SDS (w/v), 25 mM cAMP] followed by 1 ml of 50 mM Tris, pH 7.4. Samples were stored at Ϫ20°C until analyzed. The amount of cAMP formation was determined using a modification of a method reported previously using Dowex AG 50W-X4 anion exchange resin and alumina (Benya et al., 1994; Igarashi et al., 2002b) . For studying cAMP generation in Sup T 1 cells, 20 ml of medium containing 2.0 to 4.0 ϫ 10 6 cells/ml, supplemented with 2% FBS (v/v) and 2 Ci/ml [2-3 H]adenine were incubated for 48 h at 37°C. Then, the solution containing the cells was centrifuged, and the cell pellet was washed with DMEM twice, followed by suspended with 50 ml of DMEM containing 1% (w/v) BSA and 0.5 mM IBMX. Five hundred microliters of this cell solution was added to each tube with or without peptides at various concentrations and incubated for 1 h at 37°C. The procedure of termination of the reaction and column processing procedure were the same as described above. For all peptides, the EC 50 was calculated, which was the concentration of the peptide that gave half-maximal stimulation of a maximally effective concentration of VIP (1 M). The EC 50 was calculated using the curve-fitting program Kaleidagraph. 8, 9, 11, 19, 24, 25, 27, 28 ]VIP, or 125 I-VIP corresponding to 500,000 cpm (250 pM) was incubated in 1 ml of standard incubation solution in the absence of bacitracin, with or without hVPAC 1 -R/PANC cells (0.3 ϫ 10 6 cells/ml) at 37°C for 7.5 min, or hVPAC 2 -R/PANC cells (0.4 ϫ 10 6 cells/ml) at 37°C for 15 min. After incubation aliquots were centrifuged, and distribution of the radioactivity in the supernatants was analyzed by HPLC. Each supernatant (200,000 cpm) was injected onto an HPLC with a Vydac C18 column. Two-milliliter fractions were collected and radioactivity was determined.
Statistical Analysis. The results are mean Ϯ S.E.M. of three or more experiments. IC 50 and EC 50 were calculated using the curvefitting program Kaleidagraph. Statistical comparisons were made using the Student's t test.
Results

Development of Mutialaninated VIP Analogs That
Were Designed to Have a High Affinity for Human VPAC 1 -R or VPAC 2 -R (Fig. 1) . In a previous study (Igarashi et al., 2002a) , we demonstrated a simplified multialaninated analog of VIP (analog 2; present study) could be synthesized that retained high affinity for rat, guinea pig, and human VPAC 1 -R. This analog also had increased stability compared with VIP for the hVPAC 1 -R (Igarashi et al., 2002a) . However, no studies were performed on the selectivity or stability of this analog with hVPAC 2 -R. In the present study, we examined the VPAC-R selectivity of this analog and synthesized additional simplified, multialaninated analogs in an attempt to develop a highly selective VIP analog for hVPAC 1 -R and hVPAC 2 -R that might also be metabolically stable for either or both receptors.
Using the results of alanine scanning of VIP to define the amino acids essential for high-affinity interaction with the hVPAC 1 -R (Igarashi et al., 2002a ) and the hVPAC 2 -R (Igarashi et al., 2002b), we synthesized eight additional multialaninated VIP analogs that, based on single alanine substitutions, should retain high affinity for the hVPAC 1 -R or the hVPAC 2 -R. Five new analogs (analogs 1 and 3-6; Fig. 1 ) were synthesized based on the VIP pharmacophore for hVPAC 1 -R and three new analogs (analogs 7-9; Fig. 1 ) based on the VIP pharmacophore of the hVPAC 2 -R. In each case, the multialaninated simplified analogs were made by making combinations of analogs in which, when alanine was substituted alone in a given position, there was a Ͻ10-fold decrease in affinity for either the VPAC1 (Igarashi et al., 2002a) or VPAC 2 receptor (Igarashi et al., 2002b) (Fig. 1) .
Affinity of Multialanine-Substituted VIP Analogs Designed to Be hVPAC 1 -R Agonists for hVPAC 1 -R-or hVPAC 2 -R-Containing Cells. Multialaninated VIP analogs 1 and 3 to 6 retained high affinity for the hVPAC 1 -R, similar to VIP analog 2 ( Fig. 2 ; Table 1 ). The simplest, multialaninated VIP analog (VIP analog 4; Fig. 1 ) ([Ala 2, 8, 9, 11, 19, 24, 27 ]VIP) had a 6-to 7-fold decrease in the affinity compared with VIP, for the hVPAC 1 -R-containing cells. When two more alanine sub-stitutions were added in positions 25 and 28, which resulted in the VIP analog 2, it had an equal affinity to VIP for the hVPAC 1 -R, similar to that reported previously (Igarashi et al., 2002a Table 1 ). Analogs 3, 5, and 6 had a 2-to 17-fold decrease in the affinity for the hVPAC 1 -R compared with VIP and analog 2 ( Fig. 2, top ; Table 1) . To determine the possible VPAC-R selectivity of these analogs, their affinities for native hVPAC 2 -R on Sup T 1 human lymphoblastoma cells and hVPAC 2 -R stably transfected PANC1 cells were determined ( Fig. 2, bottom ; Table 1 ). VIP had a high affinity for the hVPAC 2 -R-containing cells; however, analogs 1 to 6 had a lower affinity. Analog 1 and analog 2 specifically had a 15-to 90-fold decrease in the affinity compared with VIP for the hVPAC 2 -R. When additional alanine substitutions for Met 17 , Lys 21 , Tyr 22 , or Ile 26 were made to analog 2, the affinity for hVPAC 2 -R became much lower, especially with the additional alanine substitution for Tyr 22 and Ile 26 ( Fig. 2, bottom ; Table 1 ). The resultant analogs 5 and 6 had a Ͼ4500-fold and 2500-to 3000-fold lower affinity than to VIP for hVPAC 2 -R. In terms of hVPAC-R selectivity, VIP had a 4-fold higher affinity for hVPAC 1 -R, whereas VIP analog 1 had a 36-fold higher selectivity for hVPAC 1 -R over hVPAC 2 -R and analog 2, a 150-fold selectivity for hVPAC 1 -R (Table 1 ). The additional substitution of Met 17 or Lys 21 resulted in analogs 3 and 4, respectively, which had a 150-to 200-fold higher selectivity for hVPAC 1 -R over hVPAC 2 -R (Table 1). Alanine substitution of Tyr 22 or Ile 26 in analog 2, which yielded VIP analogs 5 and 6, had the greatest selectivity for hVPAC 1 -R over hVPAC 2 -R, which were Ͼ2400-and 660-fold, respectively (Table 1) . Affinity of Multialanine-Substituted VIP Analogs Designed to Be hVPAC 2 -R Agonists for hVPAC 1 -R-or hVPAC 2 -R-Containing Cells. We synthesized three multialaninated VIP analogs that should retain high affinity for the hVPAC 2 -R (VIP analogs 7-9; Fig. 1 ) and determined their abilities to interact with hVPAC 1 -R receptors ( Fig. 3, top Fig. 1 ) as well as VIP analog 8, which had an additional alanine substitution for Ser 25 ( Fig. 1) , had a similar high affinity to VIP for the hVPAC 2 -R ( Fig. 3, bottom ; Table 1 ). However, when two additional alanine substitutions for Lys 20 and Lys 21 were added to analog 8, the resultant analog 9 had a 3-to 8-fold decrease in affinity for hVPAC 2 -R compared with VIP ( Fig.  3, bottom ; Table 1 ). We also determined their affinities for hVPAC 1 -R-containing cells (Fig. 3, top ; Table 1 ) and found that analog 7 and analog 8 showed a 2-to 3-fold and a 5-to 7-fold decrease, respectively, in affinity for hVPAC 1 -R compared with VIP. In contrast, analog 9 had a 50-fold decrease in the affinity compared with VIP for hVPAC 1 -R ( Fig. 3, top; Table 1 ). In terms of VPAC-R selectivity, each of these 3 analogs (7-9) had a 2-to 4-fold higher affinity for hVPAC 2 -R than hVPAC 1 -R, whereas VIP had a 3.7-fold higher selectivity for hVPAC 1 -R than hVPAC 2 -R (Table 1 ; Fig. 3) . Igarashi et al. (2002a,b) . The fold change in affinity compared with native VIP with a single alanine substitution in each of the indicated positions in VIP is shown from these studies (Igarashi et al., 2002a,b) . NC, Ͻ2.0-fold decrease or increase in the affinity compared with VIP; ‫,ء‬ Ն10 but Ͻ100-fold decrease in the affinity compared with VIP; ‫,ءء‬ Ն100-fold decrease in the affinity compared with VIP and for a 2-to 9.9-fold decrease the exact fold decrease is shown. The position of the alanine substitutions for each analog (labeled Ala) is shown and unchanged amino acids from VIP are indicated by "Ϫ." VIP analogs 1 to 6 were designed to possibly function as simplified high-affinity hVPAC 1 -R agonists, and VIP analogs 7 to 9 were designed to function as simplified, possibly high-affinity, hVPAC 2 -R agonists.
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Potency of Multialanine-Substituted VIP Analogs Designed to Be hVPAC 1 -R Agonists for hVPAC 1 -R or hVPAC 2 -R Activation. Activation of adenylate cyclase is the principal intracellular mediator of the action of VPAC 1 and VPAC 2 receptors (Zhou et al., 1989; Ulrich, II et al., 1998; Nicole et al., 2000) . To investigate whether these multialaninated VIP analogs functioned as agonists and if so, their potency and efficacy for hVPAC 1 -R and hVPAC 2 -R activation, we first determined the ability of VIP analogs 1 to 6, which were hVPAC 1 -R-preferring by binding studies, to stimulate cAMP generation in hVPAC 1 -R-and hVPAC 2 -R containing cells (Fig. 4; Table 2 ). Each of the six analogs had similar efficacy to VIP in stimulating cAMP generation through the hVPAC 1 -R (Fig. 4, top) . VIP had a high potency for stimulating cAMP generation in hVPAC 1 -R-containing cells with EC 50 values of 2.5 to 2.7 nM and caused a maximal stimulation with 100 nM concentration (Table 2; Fig. 4) . Except for VIP analogs 1 and 4, which showed a 2-to 4-fold decrease in potency for activating VPAC 1 -R compared with VIP, each of the other 4 VPAC 1 -R-preferring analogs (2, 3, 5, and 6) retained a high potency for the VPAC 1 -R (Fig. 4, top ; Table 2 ).
VIP had a high potency for stimulating cAMP generation via the hVPAC 2 -R, with an EC 50 of 5 nM and caused maximal stimulation at 100 to 300 nM concentration (Fig. 4, bottom) . Three of the VPAC 1 -R-preferring analogs (1, 3, and 4) had sufficient potency so that their efficacy could be determined and was shown to be equal to VIP at the VPAC 2 -R (Fig. 4 , at ASPET Journals on July 7, 2017 jpet.aspetjournals.org Downloaded from bottom). VIP analogs 1 to 6 had Ͼ90-fold lower potency than VIP for stimulating cAMP generation in hVPAC 2 -R cells. Analog 5 had the lowest potency, demonstrating Ͼ3000-fold lower potency than VIP (Fig. 4, bottom; Table 2 ). In terms of their selectivity for activating hVPAC 1 -R or hVPAC 2 -R, VIP analogs 1 to 6 had Ͼ100-fold higher selectivity for hVPAC 1 -R over hVPAC 2 -R, whereas VIP had a 2.0-fold selectivity for hVPAC 1 -R over hVPAC 2 -R (Table 2) . Based on potency, VIP analog 5 had the greater selectivity for stimulating cAMP generation, having a 15,600-fold higher selectivity for hVPAC 1 -R over hVPAC 2 -R ( Table 2) .
Potency of Multialanine-Substituted VIP Analogs (Analogs 7-9) Designed to Have Higher Affinity for the hVPAC 2 -R for hVPAC 1 -R or hVPAC 2 -R Activation. VIP analogs 7 to 9 had equal efficacy to VIP for activating either hVPAC 1 R (Fig. 5, top) or hVPAC 2 -R cells (Fig. 5, bottom) . Each of these three analogs had a similar potency to VIP for stimulating cAMP generation in VPAC 1 -R cells (Fig. 5,  top ; Table 3 ). In contrast, none of these three analogs had higher potency than VIP for stimulating cAMP generation in hVPAC 2 -R cells (Fig. 5, bottom ; Table 3 ). In terms of relative potency for VPAC-R activation, none of these three analogs had selectivity for hVPAC 2 -R over hVPAC 1 -R (Table 3) .
Stability of VIP and Multialaninated VIP Analogs Incubated with hVPAC 1 -R/PANC1 Cells or hVPAC 2 -R/ PANC1 Cells. In a previous study (Igarashi et al., 2002a) 
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at ASPET Journals on July 7, 2017 jpet.aspetjournals.org more resistant to degradation than VIP by hVPAC 1 -R/ PANC1 cells. However, in the present study, we demonstrate the VIP analog 2 has less than a 200-fold selectivity for the hVPAC 1 -R (Table 1) and thus would not be useful for in vivo receptor studies attempting to localize both hVPAC 1 -R and hVPAC 2 -R in tumors. It is unknown whether the other multialaninated analogs that retained high affinity for both hVPAC-R subtypes described in the present study (Tables 1 and 2 ) and could thus be useful for in vivo receptor characterization of both VPAC-R subtypes, were also resistant to degradation. To address this question, we prepared 125 I-analog 8 ( 125 I-Ala 2, 8, 9, 16, 19, 24, 25 ]VIP) and 125 I-analog 2 ( 125 I-Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 ]VIP) and compared the amount of degradation during an incubation with hVPAC 1 -R/PANC1 cells or hVPAC 2 -R/PANC1 cells to that seen with 125 I-VIP. As seen in Fig. 6 , left, more than 70% of 125 I-VIP was degraded during incubation with hVPAC 1 -R/PANC1 cells, whereas only 20% 125 I-analog 8 was degraded. As reported previously (Igarashi et al., 2002a) , no degradation of 125 I-analog 2 was seen under the same conditions, suggesting that analog 8 had a greater stability than VIP incubated with hVPAC 1 -R/PANC1 cells, but it was less metabolically stable than analog 2. Figure  6 , right, demonstrates that more than 70% of 125 I-VIP was degraded during an incubation with hVPAC 2 -R/PANC1 cells; however, only 20% of 125 I-analog 8 was degraded, showing that analog 8 also had a greater stability than VIP during incubation with hVPAC 2 -R/PANC1 cells. 
Discussion
The purpose of the present study was to attempt to identify simplified VIP analogs that either have high selectivity and high affinity for one subtype of VIP receptor or that were metabolically stable and retained high affinity for both VIP receptor subtypes. In a previous study (Igarashi et al., 2002a) , we identified a simplified analog of VIP, [Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 ] (analog 2 in present study), which retained high affinity for hVPAC 1 and which was synthesized after analyzing the VIP pharmacophore for VPAC 1 in human, rat, and guinea pig. In the present study, we confirmed that [Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 ] has a similar high affinity to VIP for the human VPAC 1 in both native hVPAC 1 -containing cells (T47D cells) and hVPAC 1 -transfected PANC1 cells; however, we further demonstrate this simplified VIP analog has relatively low selectivity (Ͻ170-fold) for hVPAC 1 over hVPAC 2 . Therefore, [Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 ] does not fulfill our goal of identifying a highly selective agonist for either VPAC. Furthermore, even though it is metabolically stable (Igarashi et al., 2002a) , its lower affinity for hVPAC 2 (100 -500 nM) makes it unsuitable as a high-affinity ligand for both VPACs, our second goal. In the present study, we have successfully identified simplified VIP analogs that have high selectivity and retain high affinity for the hVPAC 1 . Two of the five new, simplified VIP analogs, [Ala 2, 8, 9, 11, 19, 22, 24, 25, 27, 28 ]VIP (analog 5) and [Ala 2, 8, 9, 11, 19, [24] [25] [26] [27] [28] ]VIP (analog 6), had Ͼ2400-fold and 600-fold higher binding affinities, respectively, for hVPAC 1 over hVPAC 2 receptors. Furthermore, each of these two analogs was a fully efficacious agonist at the VPAC 1 receptor, and analog 5 had Ͼ15,000-fold greater potency for activating the hVPAC 1 compared with the hVPAC 2 , and analog 6 had Ͼ1200-fold greater potency for hVPAC 1 over hVPAC 2 . This discrepancy between potency and binding affinity for the VPAC 1 compared with native VIP is probably at least partially due to their greater metabolic stability, because each of these analogs has multialaninated substitutions similar to analogs 8 and 2 in the present study and analog 2 in a previous study (Igarashi et al., 2002a) , each of which has enhanced metabolic stability. These results demonstrate that both the simplified VIP analogs 6 and 5 may have greater selectivity than the 65-fold selectivity of [Leu 22 ]VIP for hVPAC 1 over hVPAC 2 (Gourlet et al., 1998; Bhargava et al., 2002) and at least comparable and maybe greater than the widely used VPAC 1 -selective agonist (Gourlet et al., 1997a) [Lys 15 , Arg 16 , Leu 27 ]VIP(1-7)-GRF(8-27), which is reported to have a 53-to 169-fold selectivity for rVPAC 1 over rVPAC 2 transfected into Chinese hamster ovary cells in one study (Ito et al., 2000) , but a 15,000-fold selectivity in another study (Gourlet et al., 1997a) , and a 300-to 30,000-fold selectivity in hVPAC 1 /hVPAC 2 -containing cells (Gourlet et al., 1997a; Igarashi et al., 2002b) .
In contrast to our results with the hVPAC 1 , none of the three simplified VIP analogs synthesized, based on the analysis of the VIP pharmacophore for the VPAC 2 (Igarashi et al., 2002b) , demonstrated selectivity for the hVPAC 2 . However, two of these three simplified VIP analogs [(Ala 2, 8, 9, 16, 19, 24 )VIP (analog 7) and [(Ala 2, 8, 9, 16, 19, 24, 25 )VIP (analog 8)] retained high affinity (5.6 and 7.1 nM) for the hVPAC 2 , in contrast to each of the six simplified VIP analogs (analogs 1-6) designed to have high affinity for VPAC 1 , each of which had low affinity for hVPAC 2 (468 to Ͼ30,000 nM). These results demonstrate that using the designed strategy applied in the present study, simplified analogs of VIP could be made which retained high affinity for hVPAC 2 . The lack of selectivity of these two high-affinity simplified VIP analogs (analogs 7 and 8) for VPAC 2 is in contrast to findings in other studies using different strategies that have reported finding peptides that have selectivity for VPAC 2 . The VIP-related peptide, helodermin is reported to have 15-fold higher affinity for hVPAC 2 over hVPAC 1 (Gourlet et al., 1997b) . Ro 25-1553, a cyclic analog of VIP with a lactam ring (O'Donnell et al., 1994a) , is reported to have 75-to 600-fold selectivity for hVPAC 2 over hVPAC 1 (Gourlet et al., 1997b; Ito et al., 2000; Moreno et al., 2000; Igarashi et al., 2002a) , 246-to 4300-fold for rVPAC 2 over rVPAC 1 (Ito et al., 2000) , and hexanoyl [Ala 19 , Lys 27, 28 ]VIP, to have an 800-fold selectivity for hVPAC 2 over hVPAC 1 (Langer et al., 2004) .
A review of the previous studies of the VIP pharmacophore for the VPAC1 and VPAC2 (Nicole et al., 2000; Igarashi et al., 2002a,b) provides some insights into why the approach used in the study probably resulted in selective VPAC 1 but not selective VPAC 2 agonists. In these previous studies (Gourlet et al., 1998; Nicole et al., 2000; Igarashi et al., 2002a,b) using alanine scanning to identify the VIP pharmacophore for hVPACs, a number of amino acids, particularly Thr 11 , Tyr 22 , Asn 24 , Leu 27 , and Asn 28 were more important for VPAC 2 than hVPAC 1 affinity. In these studies (Nicole et al., 2000; Igarashi et al., 2002a,b) and others (Gourlet et al., 1998) , the presence of Tyr 22 in VIP was much more important for high affinity for VPAC 2 than VPAC 1 , with the result that a single substitution of alanine in position 22 of VIP had the most profound effect on VIP's ability to interact with each VPAC subtype of any single alanine substitution. In our study, analog 5 ([Ala 2, 8, 9, 11, 18, 19, 22, 24, 25, 27, 28 ]VIP), which had the 8, 9, 16, 19, 24, 25 ]VIP and 125 I- [Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 8, 9, 11, 19, 24, 25, 27, 28 ]VIP (bottom) (500,000 cpm/ml) with or without hVPAC 1 -R/PANC1 cells (0.3 ϫ 10 6 /ml) in standard incubation solution for 7.5 min at 37°C. After incubation, supernatants containing 200,000 cpm were analyzed by HPLC. Fractions (2 ml) were collected, and radioactivity was deter- 8, 9, 16, 19, 24, 25 ]VIP (bottom) (500,000 cpm/ml) with or without hVPAC 2 -R/PANC1 cells (0.4 ϫ 10 6 /ml) in standard incubation solution for 15 min at 37°C. After incubation, supernatants containing 200,000 cpm were analyzed by HPLC. Fractions (2 ml) were collected, and radioactivity was determined. Arrows indicate the point of elution of intact 125 I peptide.
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at ASPET Journals on July 7, 2017 jpet.aspetjournals.org greatest selectivity for hVPAC 1 , was the only simplified analog to contain this substitution. The Ala 22 substitution was not included in the other five proposed VPAC 1 -selective agonists (analogs 1-4 and 6) because it has been shown to cause a 4-fold decrease in hVPAC 1 affinity (Igarashi et al., 2002a,b) , which we wanted to avoid if possible. The single substitution of alanine for Thr 11 or Leu 27 in VIP also caused a Ͼ15-fold decrease in VPAC 2 affinity with minimal changes in VPAC 1 affinity (Igarashi et al., 2002a,b) . Both of these substitutions were included in each of the six proposed simplified VPAC 1 selective agonists; however, they only resulted in a 35-to 196- in VIP caused only a 2.5-to 7.3-fold decrease in VPAC 2 affinity, with minimal effects on VPAC 1 affinity (Igarashi et al., 2002a,b) . Likewise, when they were included in the simplified proposed VPAC 1 -selective agonists (analogs 2-4 and 6), they generally had only a modest effect on increasing VPAC 1 selectivity. In contrast to the results with VPAC 1 in studies of the VIP pharmacophore for the VPAC 2 (Nicole et al., 2000; Igarashi et al., 2002a,b) , no single alanine substitution or D-amino acid substitution in VIP resulted in much greater decrease in affinity for the hVPAC 1 than the hVPAC 2 . VIP itself had a 4-fold greater affinity for hVPAC 1 than VPAC 2 . Single alanine substitution for Gln 16 or Lys 20 in VIP resulted in a 3-to 4-fold greater decrease in affinity for VPAC 1 than VPAC 2 (Igarashi et al., 2002a,b) . However, inclusion of these substitutions in analogs 7 to 9 resulted in only a 3-to 4-fold decrease in affinity of the substituted VIP analogs (analogs 7-9) for VPAC 1 , with the result these simplified analogs had nearly equal affinity for both hVPAC 1 and hVPAC 2 and therefore were not selective.
The second goal of this study was to attempt to identify a simplified VIP analog that retained high affinity for each VPAC subtype and that also might be metabolically stable. Such VIP analogs could be particularly useful for imaging of tumors overexpressing VIP receptors or for VIP receptordirected antitumor treatment. Previous studies (Bryant et al., 1976; Domschke et al., 1978) have demonstrated VIP is rapidly degraded in vivo, having a half-life less than 1 min (Bryant et al., 1976; Domschke et al., 1978) in human It has been proposed (Bryant et al., 1976; Domschke et al., 1978) that VIP is primarily degraded by being cleaved primarily at Ser 25 -Ile 26 or at Thr 7 -Asp 8 residues to yield the major products VIP(1-25) and VIP(26-28) and the minor products VIP(1-7) and VIP(8-28). All of these products are either inactive or have very low affinity for the VPAC receptors (Bolin et al., 1995) . Furthermore, another study (O'Donnell et al., 1991) extended the duration of effect by more than 17 times. We therefore anticipated that our analogs, which all had with substitutions at positions 8, 19, 25, and/or 26 of VIP, should have enhanced stability. This possibility was further supported by our previous study (Igarashi et al., 2002a ) in which we found that the multialaninated analog [Ala 2, 8, 9, 11, 19, 24, 25, 27, 28 ]VIP (analog 2) was much more resistant than VIP to degradation. A number of our results support the conclusion that we successfully achieved the second aim in the present study. First, in binding studies both analog 7 ([Ala 2, 8, 9, 16, 19, 24 8, 9, 11, 18, 19, 24, 25, 27, 28 ]VIP (analog 2), which was reported previously (Igarashi et al., 2002a) to be much more metabolically stable than VIP with hVPAC 1 -containing cells.
In conclusion, analyzing the results of studies of the VIP pharmacophore for high-affinity interaction with the hVPAC 1 or hVPAC 2 (Nicole et al., 2000; Igarashi et al., 2002a,b) , we synthesized nine simplified, polyalaninated analogs of VIP to attempt to develop high-affinity VIP analogs that were either selective for one of the two VPAC subtypes or that functioned as high-affinity agonists for each VPAC and that would be metabolically stable. Our results demonstrate that [Ala 2, 8, 9, 11, 19, 22, 24, 25, 27, 28 ]VIP (analog 5) has high affinity and Ͼ2000-fold selectivity for hVPAC 1 over hVPAC 2 . No selective VPAC2 agonists were identified. However, [Ala 2, 8, 9, 16, 19, 24, 25 ]VIP (analog 8) had high affinity and potency for both VPAC subtypes and was much more metabolically stable than VIP in cells containing each VPAC subtype. These simplified, metabolically stable analogs should be useful for investigating the role of VPAC 1 in biological and pathological processes, for enhanced imaging of tumors overexpressing VIP receptors using VIP receptor scintigraphy (Virgolini, 1997; Thakur et al., 2000 Thakur et al., , 2004 Rao et al., 2001; Bhargava et al., 2002) as well as for possible VIP receptordirected antitumor treatment for tumors overexpressing VPACs (Gotthardt et al., 2004; Moody et al., 2004; Ou et al., 2005) .
